AI assistant
GlaxoSmithKline PLC — Director's Dealing 2019
Feb 18, 2019
5262_dirs_2019-02-18_f607bd9b-0d3e-4d9c-b857-c9fae4da9d79.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 4011Q
GlaxoSmithKline PLC
18 February 2019
GlaxoSmithKline plc (the 'Company')
Shares sold to meet tax liabilities
Following the vesting of awards granted in 2016 under the GlaxoSmithKline 2009 Performance Share Plan on 14 February 2019 and as notified on 15 February 2019, the notifications that follow reflect changes in the interests of Persons Discharging Managerial Responsibilities ('PDMRs') in Ordinary Shares and in American Depositary Shares ('ADSs') of the Company arising from the sale of Ordinary Shares or ADSs to meet tax liabilities.
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.8462 | 66,159 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-02-15
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.8462 | 38,633 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-02-15
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $41.1716 | 2,311 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-02-15
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.8462 | 15,937 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-02-15
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
The sale of ADSs to meet tax liabilities further to the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $41.1716 | 16,675 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-02-15
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.8462 | 28,009 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-02-15
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Simard
b)
Position/status
President, Pharma Supply Chain
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.8462 | 3,873 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-02-15
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.8462 | 35,253 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-02-15
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.8462 | 20,283 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-02-15
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs V A Whyte
b)
Position/status
Company Secretary
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.8462 | 3,873 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-02-15
f)
Place of the transaction
London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHQVLFFKLFFBBB